OSAS

China Medical University Hospital (CMUH) Developing iDREAM to Detect Sleep Apnea at Home

Retrieved on: 
Saturday, March 30, 2024
Quanta, Cloud, Diagnosis, Sleep, UPPP, Sleep apnea, Certification, Sudden death, Intracerebral hemorrhage, Otorhinolaryngology, Patient, Heart rate, Stroke, Research, AI, Record, Snoring, Society, OSAS, Hospital, Electroencephalography, Automation, Hypertension, Respiratory system, Family, Food, Physician, ECG, Apnea, Pharmaceutical industry

TAICHUNG, March 30, 2024 /PRNewswire/ -- Snoring can be an alarming sign of obstructive sleep apnea syndrome (OSAS). Studies showed that 50% of individuals who snore may experience sleep apnea, which can lead to life-threatening conditions such as heart disease, hypertension, intracerebral hemorrhage, stroke, and even sudden death during night-time in severe cases. Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home. More than 100 patients have been in clinical trials of iDREAM. With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.

Key Points: 
  • Sleep Medicine Center at China Medical University Hospital (CMUH, Taiwan) has introduced iDREAM (Intelligent Detection of Respiratory Events through Automated Monitoring), incorporating Quanta's QOCA Portable ECG Monitoring Device, as a simple solution to efficiently detect symptoms of apnea patients during their sleep at home.
  • With this AI-powered ECG analysis, CMUH's physicians are able to identify obstructive sleep apnea syndrome (OSAS) more accurately and to reduce the time spent for diagnosis and treatment.
  • iDREAM , the home-based sleep detection system, detects ECG change from OSAS episodes and determines severity using its deep learning methodology.
  • It demonstrates 92.7% and 93.2% accuracy for sleep apnea and wake-up events (interruption of sleep from apnea), and 95.8% accuracy for defining severe OSAS (30 episodes per hour).

Aculys Pharma and Four H Initiate Research Collaboration using Wearable Devices to Study Sleep Disorders in Japan

Retrieved on: 
Tuesday, January 24, 2023
Wearables, Mobile Technology, Technology, Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Biomarker, Somnolence, Pharma, Memory, Physician, Sleep, Sleep apnea, Medicine, OSAS, Narcolepsy, Patient, Clinical trial, EDS, Heart rate, Sleep disorder, Multimedia, DX, Psychiatry, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230124006076/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230124006076/en/
    How digital devices are used to acquire information on patient sleep and daily life, and digital biomarkers are used to support physicians in patient care.
  • (Photo: Business Wire)
    In its quest to establish a new pharmaceutical model, Aculys is promoting DX (digital transformation) in clinical trials and medicine.
  • This exploratory research program will be characterized by the following three points:
    Objective understanding of narcolepsy, OSAS, and its characteristics (sleep condition, daytime sleepiness, etc.)
  • This exploratory research will allow a further accurate understanding of each patient’s sleep and lifestyle patterns, which had been difficult to measure previously.

Aculys Pharma Initiates Phase 3 Trial of Pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome

Retrieved on: 
Tuesday, January 24, 2023
Health, Neurology, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Central nervous system fatigue, Somnolence, Accident, Pharma, Sleep, Trial of the century, Sleep apnea, Arteriosclerosis, OSAS, Safety, Narcolepsy, Patient, CPAP, Depression, EMA, Diabetes, European Medicines Agency, Hypertension, EDS, Part, Quality of life, Insomnia, Pharmaceutical industry

Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, announced the initiation of a phase 3 clinical study in Japan of pitolisant—a histamine H3 receptor antagonist/inverse agonist in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS).

Key Points: 
  • Aculys Pharma, Inc. (“Aculys”), a clinical stage biopharmaceutical company focused on commercializing innovative treatments for neurological conditions, announced the initiation of a phase 3 clinical study in Japan of pitolisant—a histamine H3 receptor antagonist/inverse agonist in patients with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea syndrome (OSAS).
  • Additional study details can be found here: https://jrct.niph.go.jp/latest-detail/jRCT2031220501
    Aculys has an exclusive license to develop and commercialize pitolisant in Japan.
  • Pitolisant, developed by Paris-based Bioprojet, was approved by the European Medicines Agency (EMA) for the treatment of excessive daytime sleepiness associated with OSAS in 2021, and has since been available in the clinical setting.
  • Typical symptoms include loud snoring, daytime sleepiness, insomnia, sense of insufficient deep sleep, and systemic fatigue.

Optical Spectrum Analyzer Market to Surpass $589 Million by 2030, says P&S Intelligence

Retrieved on: 
Monday, July 25, 2022
OSAS, Electronics, Research, CAGR, OSA, Telecommunication, Technology, Industry, MEA, Mobile phone, Network equipment, Growth

Thus, the stalwarts of the industry have accepted cutting-edge distribution channels to accomplish the increasing requirement for optical spectrum analyzers.

Key Points: 
  • Thus, the stalwarts of the industry have accepted cutting-edge distribution channels to accomplish the increasing requirement for optical spectrum analyzers.
  • The telecommunications industry has the largest revenue share in the optical spectrum analyzer market.
  • The optical spectrum analyzer market in the healthcare industry will advance with the highest CAGR, of around 8%, in the years to come.
  • Browse detailed report on Optical Spectrum Analyzer Market Size, Share, Growth and Demand Forecast Report 2030
    North America is an extremely lucrative optical spectrum analyzer market for OSAs because of the existence of numerous key players, a developed economy, and the progressions in 5G technology.

Optical Spectrum Analyzer Market to Surpass $589 Million by 2030, says P&S Intelligence

Retrieved on: 
Monday, July 25, 2022
OSAS, Electronics, Research, CAGR, OSA, Telecommunication, Technology, Industry, MEA, Mobile phone, Network equipment, Growth

Thus, the stalwarts of the industry have accepted cutting-edge distribution channels to accomplish the increasing requirement for optical spectrum analyzers.

Key Points: 
  • Thus, the stalwarts of the industry have accepted cutting-edge distribution channels to accomplish the increasing requirement for optical spectrum analyzers.
  • The telecommunications industry has the largest revenue share in the optical spectrum analyzer market.
  • The optical spectrum analyzer market in the healthcare industry will advance with the highest CAGR, of around 8%, in the years to come.
  • Browse detailed report on Optical Spectrum Analyzer Market Size, Share, Growth and Demand Forecast Report 2030
    North America is an extremely lucrative optical spectrum analyzer market for OSAs because of the existence of numerous key players, a developed economy, and the progressions in 5G technology.

Dr. Clifford Brown Announces Full-Time Transition to Sleep Practice

Retrieved on: 
Thursday, January 6, 2022
Time, Academy, American Sleep Apnea Association, Family, Dental care, Philips, Star Wars, COVID-19, Insomnia, Dentistry, Sleep apnea, Dentist, American Academy, Attention, Association, Health, Sleep, Patient, Silent Night, Cancer, Jaw, Mouth, Atmosphere, Hypertension, CPAP, Philosophy, OSA, Weight gain, New York State Route 27, OSAS, Death, Headache, Pharmaceutical industry, Medical device

Dr. Brown is a member of the American Academy of Dental Sleep Medicine (AADSM) and the Academy of Clinical Sleep Disorder Disciplines.

Key Points: 
  • Dr. Brown is a member of the American Academy of Dental Sleep Medicine (AADSM) and the Academy of Clinical Sleep Disorder Disciplines.
  • According to the American Sleep Apnea Association , it is estimated that 22 million Americans are currently living with sleep apnea.
  • Dr. Brown's sleep therapy practice, Silent Night Therapy, offers effective alternative solutions for sleep apnea patients.
  • A member of the American Academy of Dental Sleep Medicine (AADSM) and the Academy of Clinical Sleep Disorder Disciplines, Dr. Brown started Silent Night Therapy to better assist sleep apnea patients.

Researchers Use Masimo ORi™, Oxygen Reserve Index, to Predict the Need for Postoperative Oxygen Therapy in Pediatric Patients with Obstructive Sleep Apnea

Retrieved on: 
Monday, October 12, 2020
Medical devices, Health, Consumer, Parenting, Children, Biotechnology, Sleep disorders, Clinical medicine, Medicine, Branches of biology, Sleep apnea, Obstructive sleep apnea, OSAS, Tonsillectomy, Masimo, Apnea, Sleep surgery, Apnea–hypopnea index

In this independent, retrospective study, researchers investigated whether Masimo ORi (Oxygen Reserve Index) could predict whether children with obstructive sleep apnea syndrome (OSAS) undergoing tonsillectomy required postoperative oxygen therapy.

Key Points: 
  • In this independent, retrospective study, researchers investigated whether Masimo ORi (Oxygen Reserve Index) could predict whether children with obstructive sleep apnea syndrome (OSAS) undergoing tonsillectomy required postoperative oxygen therapy.
  • For the remaining patients, who did not receive POT, the mean lowest values were 0.64 and 97%, respectively.
  • The researchers concluded that ORi is likely to become an index of POT in pediatric patients with OSAS.
  • Oxygen Reserve Index Predicts Postoperative Oxygen Requirement after Tonsillectomy in Children with Obstructive Sleep Apnea Syndrome.

Candy Manufacturer Goes Live on ProcessPro Global ERP Solution

Retrieved on: 
Tuesday, May 12, 2020
Business, Articles, Economy, Computer-aided engineering, ERP software, Enterprise resource planning, Information technology management, Production planning, Supply chain management, OSAS, Candy, Global

SHAKOPEE, Minn., May 12, 2020 /PRNewswire/ --ProcessPro, leading ERP software powered by Open Systems Adaptable Solutions (OSAS), is pleased to announce the successful upgrade go live of its Global software by Primrose Candy Company, a Chicago-based candy and dietary supplement contract and private label manufacturer.

Key Points: 
  • SHAKOPEE, Minn., May 12, 2020 /PRNewswire/ --ProcessPro, leading ERP software powered by Open Systems Adaptable Solutions (OSAS), is pleased to announce the successful upgrade go live of its Global software by Primrose Candy Company, a Chicago-based candy and dietary supplement contract and private label manufacturer.
  • Primrose Candy, a longtime ProcessPro client, recently transitioned to Global - the latest product offering powered by OSAS.
  • The enhancements provided by the Global solution offer the ability to place more power and flexibility in the end-users' hands, leading to an overall improved user experience.
  • Since going live, Primrose Candy is benefiting from the ease of making screen changes and adding customized fields through an intuitive drag-and-drop feature in Global's Design Studio.